Celldex Therapeutics, Inc. (NASDAQ:CLDX)

CAPS Rating: 3 out of 5

A biopharmaceutical company engaged in the discovery, development and commercialization of products that harness the human immune response to prevent and treat disease.

Results 1 - 20 of 35 : 1 2 Next »

Recs

0
Member Avatar pchop123 (78.31) Submitted: 4/10/2014 2:47:38 PM : Outperform Start Price: $15.59 CLDX Score: -10.04

nice buy-in price point for impressive biotech

Recs

0
Member Avatar TSIF (99.96) Submitted: 3/24/2014 3:37:58 PM : Outperform Start Price: $18.55 CLDX Score: -24.08

I put Celldex Therapeutics on my watch list several months ago. Possibly when it dove after ZZ pointed it down from $31 in January, but there are no current piches from ZZ or Porte to help jar my memory. ZZ noted that the oncology pipeline was early, and the $2.2B market cap was extended. So now we have it 33% cheaper, with only a $1.75B market cap and a few months later into the pipeline testing....

Since then Celldex abandoned its CDX-1135 Study (Rare Dense Deposit Disease).
Cancer Vaccines have continued to disappoint. DNDN who has one approved for prostate cancer has been less than successful at marketing it, due to cost, the 4 month media survival increase, the requirement to individually design and produce the treatment for each patient.

Overall, however while 33%, and hit REALLY hard by the two day biopharm selloff, it appears we still have some potential here. I got a nice "bottom bounce", but it may not be bottom, but mearly another leg down as we have seen for the last month.

More investigation needed.

Is this good, or bad? Well with an oncology company, any success is usually

Recs

0
Member Avatar wimmreuter (44.42) Submitted: 9/26/2013 2:22:01 PM : Outperform Start Price: $35.18 CLDX Score: -69.62

Coming down from the high 80s and now slowly being successful with their medication is the a long way to go but rewards are coming.

Recs

0
Member Avatar stockgripes (99.05) Submitted: 9/25/2013 9:52:37 AM : Underperform Start Price: $33.28 CLDX Score: +67.31

I am gonna go against the grain. Seen a good runup, the downside potential is high

Recs

0
Member Avatar Teknowizz (98.15) Submitted: 9/25/2013 3:06:12 AM : Outperform Start Price: $34.48 CLDX Score: -68.57

OK let's see whether she will run some more.
Really stopped this too early in order to bank the +300 run :)

Recs

2
Member Avatar bignr15 (< 20) Submitted: 7/7/2013 3:36:34 PM : Outperform Start Price: $21.40 CLDX Score: -47.21

Huge Growth Potential, could hit $60 in 2 years. Will be lots of ups and downs, so have long term view on this one.

Recs

0
Member Avatar FoolsLint (< 20) Submitted: 7/6/2013 4:59:20 PM : Outperform Start Price: $21.40 CLDX Score: -47.21

The demand for cancer cure. The success this company is having . The effect that this company is having on breast cancer is a very good start.

Recs

0
Member Avatar TheStockDoctor (< 20) Submitted: 6/11/2013 7:15:03 AM : Outperform Start Price: $15.14 CLDX Score: -20.08

Pipeline is strong and competition is minimal.

Recs

1
Member Avatar MyManDon1 (< 20) Submitted: 7/20/2012 11:38:21 AM : Outperform Start Price: $5.38 CLDX Score: +128.43

1) market cap of only $300MM
2) has cash on hand to get through PIII with leading drugs
3) owns most important drugs outright keeping significant potential for homegrown profits inhouse and/or leaving room for partnership and/or full buyout
4) multiple drugs in pII providing cushion agains setback (i.e. limited downside risk)
5) management/science presentations exhibit sound planning and strategy that is needed to succeed
6) partnership activity is picking up due to patent cliffs at many big pharmas

Recs

1
Member Avatar rangarajud (55.88) Submitted: 5/16/2012 5:31:51 PM : Outperform Start Price: $4.47 CLDX Score: +178.28

great stock with huge pipeline and promising drug status on May 23rd 2012 will send this stock north of 7$.

Recs

1
Member Avatar stainsolution (71.46) Submitted: 4/24/2012 3:24:49 PM : Outperform Start Price: $3.96 CLDX Score: +223.24

ASCO run---might be a little early here.

Recs

1
Member Avatar RBuskey106 (63.41) Submitted: 3/21/2012 8:22:30 PM : Outperform Start Price: $4.77 CLDX Score: +165.44

ASCO pick

Recs

0
Member Avatar solanZRaider (< 20) Submitted: 5/16/2011 12:43:10 PM : Outperform Start Price: $3.52 CLDX Score: +263.32

irishred1

Recs

0
Member Avatar Khatte (< 20) Submitted: 4/11/2011 8:54:38 PM : Outperform Start Price: $4.10 CLDX Score: +205.81

It appears that CLDX is entering phase III of clinical trials on it's new immune based cancer treatments with strong results in earlier phases.

Recs

0
Member Avatar sjc40 (32.47) Submitted: 2/18/2011 6:57:39 PM : Outperform Start Price: $3.60 CLDX Score: +253.75

as a physician i think this is the best of all biotech

Recs

0
Member Avatar julianna8 (< 20) Submitted: 10/7/2010 4:34:28 PM : Outperform Start Price: $4.32 CLDX Score: +169.02

taking a gamble on this one.

Recs

1
Member Avatar KattyKay (80.25) Submitted: 10/6/2010 3:12:13 PM : Outperform Start Price: $4.50 CLDX Score: +155.43

Celldex Therapeutics, Inc. has strong science underlying it's drug candidates. The therapeutic use of a vaccine to 'teach' the immune system to control or remove the cancer cells is a unique niche that has few other candidate drugs. The clinical trial data is quite promising that this approach works in humans as well as in animals. Given the good clinical data so far, a new clinical development partner will be easier to find and negotiate with. This pick is a long-term pick though.

Recs

1
Member Avatar TMFBreakerJava (99.51) Submitted: 10/5/2010 3:42:08 PM : Outperform Start Price: $4.74 CLDX Score: +140.04

Startlingly good results released today in a glioblastoma drug trial. This is a vaccine style treatment, a domain which has been pursued without success until recent DNDN breakthrough in prostate cancer

Recs

0
Member Avatar czorbs99 (< 20) Submitted: 6/18/2010 10:58:13 AM : Outperform Start Price: $4.99 CLDX Score: +118.40

Way undervalued with late stage products, as well as alot of cash to hold them without turning to market for $$. ASCO results were good and Pfe is going forward...whats not to like with this company?

Recs

0
Member Avatar noelart (< 20) Submitted: 6/18/2010 4:57:01 AM : Outperform Start Price: $5.23 CLDX Score: +105.60

Product pipeline had good results in Phase II trials and company has a good balance sheet. 70% of Patients in CDX-110 trials were diagnosed with non-recurrence of glioblastoma brain cancer or significantly reduced. Survival rates are v good at 5.5 months (phase II is still on-going) with a lot of patients from previous 'duke university' trial still alive after 1.5 years. DNDN got FDA approval for Provenge on the merits of 4 months survival rate from Phase III studies with prostate cancer patients, I believe CDX-110 can easily exceed this benchmark. Phase II trials end next November, sometime this September PFE and CLDX will announce Phase III details - most probably CLDX will rally when that news is out.

Results 1 - 20 of 35 : 1 2 Next »

Featured Broker Partners


Advertisement